2026 Reimbursement Policy for Neratinib/Neratinib

Neratinib/Neratinib (Neratinib) is an oral targeted anti-cancer drug, mainly used to treat patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. It is a tyrosine kinase inhibitor that can inhibit the excessive activation ofHER2 receptor, thereby inhibiting the growth and spread of cancer cells.

In China, the original drug of neratinib is already on the market and has been included in the Class B National Medical Insurance List. However, the reimbursement policy is relatively strict, and patients must meet specific indications to receive medical insurance reimbursement. Specifically, neratinib is mainly used for HER2-positive early breast cancer patients as intensive adjuvant therapy after receiving adjuvant therapy with standard therapies such as trastuzumab (Herceptin). Its indications mainly include patients who have received trastuzumab treatment and have not experienced disease recurrence or other adverse reactions.

The regulations on reimbursement scope mean that only patients who meet these conditions can receive certain cost compensation through medical insurance. This has played a positive role in reducing the treatment burden on patients, but it still has certain limitations. In addition, neratinib's 40mg*180 tablets are relatively expensive, about RMB 7,000 per box. Therefore, for patients, although they are reimbursed by medical insurance, the cost of treatment cannot be ignored.

Therefore, patients need to pay special attention to its indications and medical insurance coverage when using neratinib to ensure that they meet relevant conditions. For patients who are not eligible for reimbursement, they may need to rely on out-of-pocket purchases, which will increase the patient's financial burden. When choosing to use neratinib, it is recommended that patients discuss it in detail with their doctor to confirm whether the treatment plan meets the medical insurance reimbursement standards to reduce treatment costs.

Reference materials:https://en.wikipedia.org/wiki/Neratinib